Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*

Background:Septic shock represents the major cause of infection-associated mortality in the intensive care unit. The possibility that combination antibiotic therapy of bacterial septic shock improves outcome is controversial. Current guidelines do not recommend combination therapy except for the express purpose of broadening coverage when resistant pathogens are a concern. Objective:To evaluate the therapeutic benefit of early combination therapy comprising at least two antibiotics of different mechanisms with in vitro activity for the isolated pathogen in patients with bacterial septic shock. Design:Retrospective, propensity matched, multicenter, cohort study. Setting:Intensive care units of 28 academic and community hospitals in three countries between 1996 and 2007. Subjects:A total of 4662 eligible cases of culture-positive, bacterial septic shock treated with combination or monotherapy from which 1223 propensity-matched pairs were generated. Measurements and Main Results:The primary outcome of study was 28-day mortality. Using a Cox proportional hazards model, combination therapy was associated with decreased 28-day mortality (444 of 1223 [36.3%] vs. 355 of 1223 [29.0%]; hazard ratio, 0.77; 95% confidence interval, 0.67-0.88; p = .0002). The beneficial impact of combination therapy applied to both Gram-positive and Gram-negative infections but was restricted to patients treated with &bgr;-lactams in combination with aminoglycosides, fluoroquinolones, or macrolides/clindamycin. Combination therapy was also associated with significant reductions in intensive care unit (437 of 1223 [35.7%] vs. 352 of 1223 [28.8%]; odds ratio, 0.75; 95% confidence interval, 0.63-0.92; p = .0006) and hospital mortality (584 of 1223 [47.8%] vs. 457 of 1223 [37.4%]; odds ratio, 0.69; 95% confidence interval, 0.59-0.81; p < .0001). The use of combination therapy was associated with increased ventilator (median and [interquartile range], 10 [0-25] vs. 17 [0-26]; p = .008) and pressor/inotrope-free days (median and [interquartile range], 23 [0-28] vs. 25 [0-28]; p = .007) up to 30 days. Conclusion:Early combination antibiotic therapy is associated with decreased mortality in septic shock. Prospective randomized trials are needed.

[1]  H. Neu.  Synergy and Antagonism of Fluoroquinolones with Other Classes of Antimicrobial Agents , 2012, Drugs.

[2]  Anand Kumar,et al.  A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study , 2010, Critical care medicine.

[3]  M. Mathru.  Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock , 2010 .

[4]  Anand Kumar,et al.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. , 2009, Chest.

[5]  S. Bagshaw,et al.  Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy , 2009, Intensive Care Medicine.

[6]  Anand Kumar,et al.  Early intravenous unfractionated heparin and mortality in septic shock* , 2008, Critical care medicine.

[7]  A. Marchese,et al.  In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa. , 2008, The new microbiologica.

[8]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[9]  H. Seifert,et al.  Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[10]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[11]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[12]  L. Saravolatz,et al.  Monotherapy versus combination therapy. , 2006, The Medical clinics of North America.

[13]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[14]  Til Stürmer,et al.  Indications for propensity scores and review of their use in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.

[15]  M. Mufson,et al.  Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  I. Kobayashi,et al.  In vitro synergistic effects of double combinations of β-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[17]  G. Tillotson,et al.  The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. , 2005, Chest.

[18]  L. Leibovici,et al.  Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. , 2005, The Lancet. Infectious diseases.

[19]  C. Wallrauch,et al.  In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  D. Milatovic,et al.  Development of resistance during antibiotic therapy , 1987, European Journal of Clinical Microbiology.

[21]  James S. M. Tan,et al.  Nonantimicrobial effects of antibacterial agents. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Labro.  Cellular and molecular effects of macrolides on leukocyte function. , 2004, Current pharmaceutical design.

[23]  J. Handelsman,et al.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. , 2004, The Lancet. Infectious diseases.

[24]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[25]  Anders Larsson,et al.  Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock , 2003, Critical care.

[26]  M. Mufson,et al.  Lack of Synergy of Erythromycin Combined with Penicillin or Cefotaxime against Streptococcus pneumoniae In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[27]  I. Odenholt,et al.  Variation in the Propensity to Release Endotoxin after Cefuroxime Exposure in Different Gram-negative Bacteria: Uniform and Dose-dependent Reduction by the Addition of Tobramycin , 2003, Scandinavian journal of infectious diseases.

[28]  T. van der Poll,et al.  Pharmacokinetic‐pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor‐α and interleukin‐6 production , 2001, Fundamental & clinical pharmacology.

[29]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[30]  T. Calandra,et al.  Antibiotics in sepsis , 2001, Intensive Care Medicine.

[31]  L. Valera,et al.  Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. , 2001, International journal of antimicrobial agents.

[32]  Lori S. Parsons.  Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .

[33]  E. Bouza,et al.  Monotherapy versus combination therapy for bacterial infections. , 2000, The Medical clinics of North America.

[34]  M. Labro.  ' ' Immuno-Fairy Tales ' ' ? Phagocyte Functions : Immunomodulation Interference of Antibacterial Agents with , 2000 .

[35]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[36]  J. Remington,et al.  Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. , 1999, International journal of antimicrobial agents.

[37]  V. Yu,et al.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. , 1999, International journal of antimicrobial agents.

[38]  J. Remington,et al.  Effect of Trovafloxacin on Production of Cytokines by Human Monocytes , 1998, Antimicrobial Agents and Chemotherapy.

[39]  M. Postelnick,et al.  The utility of aminoglycosides in an era of emerging drug resistance. , 1998, International journal of antimicrobial agents.

[40]  J. García-de-Lomas,et al.  In vitro Interaction between Ofloxacin and Cefotaxime against Gram-Positive and Gram-Negative Bacteria Involved in Serious Infections , 1998, Chemotherapy.

[41]  L. Goldman,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, JAMA.

[42]  J. Washington,et al.  Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. , 1996, Diagnostic microbiology and infectious disease.

[43]  Claude Carbón,et al.  Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model , 1996, Antimicrobial agents and chemotherapy.

[44]  S. Kohno,et al.  Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. , 1994, Chest.

[45]  K. Bowker,et al.  Synergy testing of macrolide combinations using the chequerboard technique. , 1993, The Journal of antimicrobial chemotherapy.

[46]  R. A. Castillo-Lara,et al.  Definitions for sepsis and organ failure. , 1993, JAMA.

[47]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[48]  M. Jackson,et al.  Definitions of infection for surveillance in long-term care facilities. , 1991, American journal of infection control.

[49]  C. Feldman,et al.  Klebsiella pneumoniae bacteraemia at an urban general hospital. , 1990, The Journal of infection.

[50]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[51]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[52]  T. Calandra,et al.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. , 1987, The New England journal of medicine.

[53]  H. Giamarellou.  Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. , 1986, The American journal of medicine.

[54]  J. Tenney,et al.  A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. , 1986, The American journal of medicine.

[55]  G. Ruoff.  The pain of osteoarthritis. , 1986, The American journal of medicine.

[56]  C. Cordon-Cardo,et al.  Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. , 1986, The American journal of medicine.

[57]  H. Standiford,et al.  Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. , 1986, The American journal of medicine.

[58]  T. Calandra,et al.  Immunocompromised animal models for the study of antibiotic combinations. , 1986, The American journal of medicine.

[59]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[60]  A. Chow,et al.  Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections , 1983, Antimicrobial Agents and Chemotherapy.

[61]  J. Klastersky,et al.  Synergistic combinations of antibiotics in gram-negative bacillary infections. , 1982, Reviews of infectious diseases.

[62]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[63]  W. R. Mccabe,et al.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. , 1980, The American journal of medicine.

[64]  W. Hewitt,et al.  Antimicrobial synergism in the therapy of gram-negative rod bacteremia. , 1978, Chemotherapy.

[65]  T. Yoshikawa,et al.  In Vitro Antibacterial Activity of Amikacin and Ticarcillin, Alone and in Combination, Against Pseudomonas aeruginosa , 1978, Antimicrobial Agents and Chemotherapy.

[66]  N. E. Allen,et al.  Mechanism of Penicillin-Erythromycin Synergy on Antibiotic-Resistant Staphylococcus aureus , 1978, Antimicrobial Agents and Chemotherapy.

[67]  F. Fekety,et al.  Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. , 1977, The Journal of infectious diseases.

[68]  R. Sutherland,et al.  Synergy Between Ticarcillin and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae In Vitro and In Vivo , 1977, Antimicrobial Agents and Chemotherapy.

[69]  H. Standiford,et al.  Comparative Activity of Tobramycin, Amikacin, and Gentamicin Alone and with Carbenicillin Against Pseudomonas aeruginosa , 1974, Antimicrobial Agents and Chemotherapy.

[70]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[71]  G. Jackson,et al.  Gram-Negative Bacteremia. II. Clinical, Laboratory, and Therapeutic Observations. , 1962 .